1345 W. 16th Street
Xylogenics is a biotech company, with a well-earned expertise in yeast genomics and the ethanol industry. Xylogenics is leading the advancement of current biochemical production and enable diversification to higher margin bio-chemicals such as enzymes, alcohols, nutraceuticals, and organic compounds.
Xylogenics is leading the advancement of current biochemical production and enable diversification to higher margin bio-based chemicals such as enzymes, alcohols, nutraceuticals, and organic compounds.
Fuel ethanol is a stepping-stone for Xylogenics, as secondary targets- nutraceuticals and biosimilars are already being pursued. In the nutraceutical market a prime candidate is beta-glucan, naturally present in yeast, and is predicted to be worth $1.055 billion by 2021. Biosimilars also are a rapidly expanding market, predicted to be worth $11 Billion by 2020, with a 22% CAGR. Xylogenics’ hopes to have initial products in both of these target markets by 2018. Even though Xylogenics’ core yeast strain has already achieved GRAS (Generally Recognized As Safe) status by the FDA, Xylogenics is pursuing products with the shortest route to market first, and will later expand into lengthier endeavors.
In short, Xylogenics is on the leading edge of the biochemical market, and will quickly grow to become a premier chemical company, with strain design as its core. Xylogenics will use systems biology to create sustainable solutions for a variety of rapidly expanding markets.